News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
348,331 Results
Type
Article (10354)
Company Profile (16)
Press Release (337961)
Multimedia
Podcasts (5)
Webinars (2)
Section
Business (98063)
Career Advice (410)
Deals (20762)
Drug Delivery (33)
Drug Development (45980)
Employer Resources (31)
FDA (9182)
Job Trends (9419)
News (177422)
Policy (18592)
Tag
Academia (1693)
Accelerated approval (5)
Adcomms (12)
Allergies (58)
Alliances (24029)
ALS (64)
Alzheimer's disease (887)
Antibody-drug conjugate (ADC) (77)
Approvals (9229)
Artificial intelligence (170)
Autoimmune disease (15)
Automation (10)
Bankruptcy (180)
Best Places to Work (8962)
BIOSECURE Act (3)
Biosimilars (39)
Biotechnology (18)
Bladder cancer (59)
Brain cancer (23)
Breast cancer (180)
Cancer (1621)
Cardiovascular disease (115)
Career advice (353)
Career pathing (4)
CAR-T (123)
Cell therapy (295)
Cervical cancer (18)
Clinical research (38340)
Collaboration (547)
Compensation (138)
Complete response letters (12)
COVID-19 (1292)
CRISPR (29)
C-suite (146)
Cystic fibrosis (55)
Data (1750)
Denatured (1)
Depression (30)
Diabetes (170)
Diagnostics (4171)
Digital health (13)
Diversity (2)
Diversity, equity & inclusion (12)
Drug discovery (79)
Drug pricing (49)
Drug shortages (19)
Duchenne muscular dystrophy (57)
Earnings (41897)
Editorial (15)
Employer branding (1)
Employer resources (27)
Events (53293)
Executive appointments (429)
FDA (10280)
Friedreich's ataxia (2)
Frontotemporal dementia (7)
Funding (465)
Gene editing (70)
Generative AI (13)
Gene therapy (194)
GLP-1 (267)
Government (2560)
Grass and pollen (2)
Guidances (125)
Healthcare (14316)
Huntington's disease (10)
IgA nephropathy (24)
Immunology and inflammation (58)
Indications (27)
Infectious disease (1385)
Inflammatory bowel disease (95)
Inflation Reduction Act (6)
Influenza (43)
Intellectual property (67)
Interviews (68)
IPO (11082)
IRA (18)
Job creations (804)
Job search strategy (297)
Kidney cancer (8)
Labor market (8)
Layoffs (76)
Leadership (5)
Legal (3927)
Liver cancer (54)
Lung cancer (232)
Lymphoma (111)
Machine learning (5)
Management (11)
Manufacturing (184)
MASH (47)
Medical device (8998)
Medtech (8999)
Mergers & acquisitions (10165)
Metabolic disorders (388)
Multiple sclerosis (49)
NASH (10)
Neurodegenerative disease (48)
Neuropsychiatric disorders (9)
Neuroscience (1238)
NextGen: Class of 2025 (4949)
Non-profit (3941)
Obesity (181)
Opinion (94)
Ovarian cancer (65)
Pain (63)
Pancreatic cancer (63)
Parkinson's disease (99)
Partnered (5)
Patents (178)
Patient recruitment (85)
Peanut (29)
People (27545)
Pharmaceutical (9)
Pharmacy benefit managers (9)
Phase I (12277)
Phase II (17034)
Phase III (12567)
Pipeline (1001)
Policy (42)
Postmarket research (1040)
Preclinical (4606)
Press Release (58)
Prostate cancer (62)
Psychedelics (17)
Radiopharmaceuticals (175)
Rare diseases (235)
Real estate (2268)
Recruiting (10)
Regulatory (13495)
Reports (16)
Research institute (1423)
Resumes & cover letters (64)
Rett syndrome (4)
RNA editing (2)
RSV (25)
Schizophrenia (45)
Series A (80)
Series B (53)
Service/supplier (2)
Sickle cell disease (35)
Special edition (16)
Spinal muscular atrophy (67)
Sponsored (15)
Startups (1267)
State (1)
Stomach cancer (6)
Supply chain (36)
Tariffs (5)
The Weekly (3)
Vaccines (312)
Venture capitalists (14)
Weight loss (94)
Women's health (11)
Worklife (4)
Date
Today (85)
Last 7 days (630)
Last 30 days (1927)
Last 365 days (21095)
2025 (7336)
2024 (23611)
2023 (27117)
2022 (31296)
2021 (34737)
2020 (36418)
2019 (34741)
2018 (25462)
2017 (18182)
2016 (17697)
2015 (19894)
2014 (10005)
2013 (6821)
2012 (7190)
2011 (7968)
2010 (7172)
Location
Africa (283)
Alabama (37)
Alaska (6)
Arizona (98)
Arkansas (8)
Asia (25442)
Australia (5299)
California (3972)
Canada (1387)
China (457)
Colorado (199)
Connecticut (200)
Delaware (90)
Europe (41468)
Florida (636)
Georgia (114)
Idaho (36)
Illinois (376)
India (21)
Indiana (265)
Iowa (2)
Japan (124)
Kansas (31)
Kentucky (19)
Louisiana (10)
Maine (53)
Maryland (683)
Massachusetts (2859)
Michigan (122)
Minnesota (218)
Mississippi (2)
Missouri (56)
Montana (30)
Nebraska (17)
Nevada (52)
New Hampshire (57)
New Jersey (1389)
New Mexico (23)
New York (1294)
North Carolina (596)
North Dakota (5)
Northern California (1792)
Ohio (138)
Oklahoma (9)
Oregon (15)
Pennsylvania (903)
Puerto Rico (12)
Rhode Island (23)
South America (495)
South Carolina (23)
South Dakota (1)
Southern California (1519)
Tennessee (69)
Texas (610)
United States (15612)
Utah (118)
Virginia (125)
Washington D.C. (32)
Washington State (418)
West Virginia (2)
Wisconsin (24)
348,331 Results for "origin agritech limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Origin Agritech Announces Long-Term Revenue Projections Across Key Product Lines Through 2029
July 23, 2024
·
2 min read
/C O R R E C T I O N -- Origin Agritech Limited/
Origin Agritech Ltd., an agriculture technology company, announced that the company has received an order for its hybrid corn worth RMB240 million, or roughly $35 million, from Muyuan Foods.
July 27, 2022
·
5 min read
Press Releases
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
April 4, 2025
·
6 min read
Origin Agritech Receives a $35 Million Order from Muyuan Foods
Origin Agritech Ltd., an agriculture technology company, announced that the company has received an order for its hybrid corn worth RMB240 million, or roughly $35 million, from Muyuan Foods.
July 27, 2022
·
4 min read
Origin Agritech and China Agricultural University to Collaborate on Research of Molecular Design of Corn Using CRISPR
Origin Agritech Ltd. (NASDAQ: SEED) (the “Company” or “Origin”), an agriculture technology company, today announced that it has entered into collaboration agreement with China Agricultural University for the research of molecular design in corn.
September 21, 2021
·
4 min read
Genetown
Cellular Origins and Cell and Gene Therapy Catapult Collaborate to Demonstrate Universal Automation of CGT Manufacturing
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies, and the Cell and Gene Therapy Catapult, an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, announced a collaboration to demonstrate universal automation of CGT manufacturing.
May 29, 2024
·
4 min read
Origin Agritech Ltd Utilized Gene Editing Technology to Create New Corn Traits
Origin Agritech Ltd., an agriculture technology company, announced that it has successfully utilized gene editing technology to create new corn traits.
March 8, 2021
·
4 min read
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Policy
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
PharmaTher Holdings Ltd. announced receipt of an Amendment Acknowledgment Letter for its Priority Original Abbreviated New Drug Application for Ketamine from the U.S. Food and Drug Administration and assigned a Generic Drug User Fee Amendments of 2022 goal date of October 29, 2024.
May 10, 2024
·
5 min read
Pharm Country
Origin Life Sciences Abstract Accepted for Presentation at 2024 Military Health System Research Symposium (MHSRS) Discussing Innovative Technologies and Devices for Treatment of Battlefield Wounds in Prolonged Care to Prevent Infection
Origin Life Sciences, Inc. announced that the Company’s abstract, titled: “NO: a Novel, Pathogen-Agnostic Therapy for Treatment-Resistant Wound Infections in the Warfighter,” has been accepted for presentation at 2024 Military Health System Research Symposium.
June 11, 2024
·
6 min read
1 of 34,834
Next